Medikit (7749) Q1 2027 earnings summary

Executive summary

• Net sales rose 8.1% year-over-year to ¥6,365 million for the quarter ended June 30, 2026, with operating profit up 23.8% to ¥1,266 million and profit attributable to owners of parent up 33.5% to ¥523 million.

• Comprehensive income nearly doubled year-over-year, reaching ¥588 million, reflecting strong operational and financial performance.

Financial highlights

• Gross profit increased to ¥2,456 million from ¥2,218 million year-over-year, with gross margin improving.

• Operating profit margin improved, with operating profit before goodwill amortization at ¥1,320 million, up 22.6% year-over-year.

• Basic earnings per share rose to ¥36.15 from ¥26.83 year-over-year.

• Total assets stood at ¥52,855 million and net assets at ¥46,645 million as of June 30, 2026.

Outlook and guidance

• Full-year net sales forecast at ¥25,800 million, up 8.5% year-over-year, with operating profit expected to rise 0.6% to ¥4,300 million.

• Profit attributable to owners of parent projected to decline 5.2% to ¥2,850 million for the fiscal year ending March 31, 2027.

• No revisions to previously announced earnings or dividend forecasts.